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It is unclear whether patients with Hashimoto thyroiditis (HT) are predisposed to develop thyroid
nodules and/or thyroid cancer. The objective of our study was therefore to assess the prevalence of
thyroid nodules and/or cancer in patients with HT and to look for possible prognostic factors. A ret-
rospective survey of 904 children/adolescents with HT (709 females, 195 males) regularly followed in
nine Italian centers of pediatric endocrinology was performed. Median period of follow-up was 4.5 years
(1.2 to 12.8 years). We evaluated free T4, TSH, thyroid peroxidase antibody (TPOAb), thyroglobulin
antibodies, and thyroid ultrasound yearly. One hundred seventy-four nodules were detected, with an
annual incidence rate of 3.5%. Ten nodules were malignant (8 papillary and 2 papillary follicular
variant), giving a 5.7% prevalence of cancer among patients with nodules. The severity of hypo-
echogenity at ultrasound, TPOAb, and free T4 serum concentrations were predictive for the appearance
of new nodules. Furthermore, a positive correlation was observed between TPOAb titer and the de-
velopment of thyroid cancer. In conclusion, HT seems to influence the development of thyroid nodules,
but not cancer in children and adolescents.
Copyright © 2019 Endocrine Society
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It is unclear whether patients with Hashimoto thyroiditis (HT) are predisposed to the de-
velopment of thyroid nodules and/or thyroid cancer. Different approaches have led to dis-
cordant findings in adult subjects. A clear association between HT and differentiated thyroid
cancer (DTC), mainly papillary, has been reported in surgical series [1–6]. However, this
association was not found in patients with nodular pathology without suspicion of malig-
nancy who underwent fine needle biopsy (FNA) and cytological studies [7–13] Because the
Abbreviations: CV, coefficient of variation; DTC, differentiated thyroid cancer; FNA, fine-needle aspiration; HT, Hashimoto thy-
roiditis; PTC, papillary thyroid carcinoma; T1DM, type 1 diabetesmellitus; TgAb, thyroglobulin antibody; TPOAb, thyroid peroxidase
antibody; TS, thyroid score.
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surgically treated patients are those considered at higher risk of malignancy, the association
between HT and DTC based on surgical pathology may be secondary to selection bias.
Nodular pathology and cancer are rarely observed in children and adolescents compared
with the adult population. In a survey of 5179 healthy children performed in 1975, Rallison
et al. [14] reported a frequency of nodules of 1.8%. However, in this study the presence of
thyroid nodules was assessed by the poorly sensitive method of palpation. Furthermore, the
prevalence of autoimmunity has increased in recent decades and so it may no longer be
appropriate to make comparisons to a study performed more than 40 years ago. More recent
studies that use ultrasound imaging, reported a prevalence of 0.2% to 5.1% [15–17].
Thyroid nodules in children carry a greater risk of malignancy compared with adults [18].
However, there are few published data on the frequency of the development of thyroid cancer in
children and adolescents with thyroid nodules. Niedziela [19] reviewed 18 studies published
between 1960 and 2004 and reported a frequency of 9.2% to 50% based on surgical specimens.
More recently, studies based on cytological/histological evaluation reported a frequency ofmore
than 16% [20–22], which is greater than that seen in adult patients (2.3%) [23, 24].
Nethertheless, thyroid cancer is a rare condition in children and adolecents with an
average age-adjusted rate of 0.59 per 100,000 cases [25]. A higher prevalence of up to 36 to 48
per 100,000 can be found in children exposed to radiation, such as in Fukushima after the
FukushimaDaiichi nuclear power plant accident [26]. Whether the presence of HT influences
the development of nodules and/or cancer in children is even more debated. The data are of
poor quality, usually based on retrospective cross-sectional studies and the diagnosis is
commonly made on clinical grounds. An Italian multicenter study on 365 children with HT
reported the occurrence of thyroid nodularity and cancer in 31% and 3% of the patients,
respectively [24]. Kambalapalli et al. [27] found an equal incidence of thyroid nodules and
DTC in thyroid peroxidase antibody (TPOAb)-positive and -negative patients.
HT is a frequent condition in children and adolescents, and therefore, a better un-
derstanding of the risk for developing cancer is of great importance. This retrospective study
was designed to investigate the role of HT on the development of thyroid nodules and cancer
in a large group of children and adolescents followed-up for up to 12 years.
1. Subjects and Methods
A. Study Protocol
Between December 2003 and July 2016, 3754 patients with HT were regularly followed up in
nine Italian centers of pediatric endocrinology. From this cohort, we included in this study
904 children/adolescents (709 females and 195 males) for whom free T4, TSH, TPOAb,
thyroglobulin antibody (TGAb) measurement, thyroid ultrasound, and auxological data were
available from the time of diagnosis and during the follow-up period. Median follow up was
4.5 years (1.2 to 12.8 years). The diagnosis of HT was based on the presence of TPOAb and/or
TGAb, and/or the typical ultrasound pattern. Thyroid function (free T4 and TSH) and
auxological data were obtained at diagnosis and yearly during follow-up. Thyroid ultrasound
was performed at diagnosis and every other year in the subjects without nodularity, and
yearly in those with nodules. Hypothyroidism was defined by a TSH level.10 mU/L and free
T4 within or below the normal range, whereas subclinical hypothyroidism was defined by a
TSH between 5 and 10 mU/L and free T4 in the normal range.
In addition to HT, 58 patients also had celiac disease, 12 had type 1 diabetes mellitus
(T1DM), 31 had vitiligo, 22 had alopecia, and 2 had Addison disease. Two females had T1DM
and celiac disease, 3 females had celiac disease and vitiligo, 1 male had T1DM and alopecia,
and 3 males and 1 female had vitiligo and alopecia. Sixteen patients had Turner syndrome (1
also associated with celiac disease) and 10 (7 females and 3 males) had Down syndrome. A
positive family history for autoimmune disease was present in 355 (39.26%, 272 females) of
patients. Consent has been obtained from each patient or subject after full explanation of the
purpose and nature of all procedures used. Formal ethical approval by an ethical committee is
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not required in accordance with the Italian regulation for noninterventional (observational)
retrospective studies concerning human beings (AIFA Guidelines for Observational Studies,
see www.AIFA.gov). All procedures performed in the study were in accordance with the
ethical standards of the institutional and/or national research committee and with the 1964
Helsinki Declaration and its later amendments or comparable ethical standards.
B. Thyroid Ultrasound and Thyroid Score
Ultrasound was performed in each center using a 9 to 13 MHz transducer. The volume of the
thyroid gland is the sum of the volume of each lobe, calculated using the formula for a prolate
ellipse: volume = 0.5 3 (L 3 D 3 W) were L is the length (L), (D) is the anterior-posterior
depth, and (W) is the transverse width of the gland. The presence of goiter was defined as a
thyroid volume of more than 2 SD according to the normal values reported by Vitti et al. [28].
A hypoechogenic signal was considered a typical ultrasound pattern for the diagnosis of HT.
Alterations of echogenicity and homogeneity of the parenchyma were further quantified
according to a pediatric scoring system [29]. Score 0: normal; score 1: mild parcelled
hypoechogenicity; score 2: severe parcelled hypoechogenicity; score 3: mild generalized
hypoechogenicity; score 4: severe generalized hypoechogenicity; score 5: near-anechogenicity.
We refer to this score system throughout the manuscript as the thyroid score (TS). The
presence of cervical adenopathy was also evaluated by ultrasound in all patients.
C. Thyroid Nodules
Criteria for FNA of a thyroid nodule were diameter .1 cm or diameter 0.5 to 1 cm with an
echographic pattern suspicious for malignancy (solid nodule, internal calcifications, hypo-
echoic, irregular margins, taller than wider on transverse view, absence of halo). Cytological
findings were evaluated according to the Italian consensus for the classification and reporting
of thyroid cytology [30]. The presence of cervical adenopathy was also checked and post-
operative staging in patients with thyroid cancer was performed according to the eighth
edition of the AJCC/TNM classification system for DTC, based on the staging of the primary
tumor (T), lymph nodes (N) and distant metastases (M) [31]. There was no central review of
the thyroid ultrasound, FNA, and/or surgical pathology.
D. Assays
From 2006, serum TSH, free T4, TGAb, and TPOAb were measured by chemiluminescent
immunometric assays in all participating centers. TSH [32] and free T4 [33] were measured
using reagents provided by Roche Diagnostics GmbH (Manheim, Germany); the intra- and
interassay coefficient of variation (CV) for TSHwere 2.7% and 3.2%, with a sensitivity limit of
0.005 mU/L. For free T4 the intra- and interassay CV were 1.8% and 2.6%, and the limit of
sensitivity was 0.08 pg/mL. TGAb [34] and TPOab [35] were measured using Immulite 2000
Anti-TG Ab (DPC, LA, Siemens Medical Solutions-Diagnostics, Malvern, PA). For TGab the
intra- and interassay CVwere 3.2% and 4.6%, and the limit of sensitivity was of 2.2U/mL. For
TPOAb the intra- and interassay CV were 5.2% and 3.2%, with a sensitivity limit of 5 U/mL.
Prior to this, laboratory measurements were performed using different methods by the
participating centers.
E. Statistical Analysis
Data are shown as mean 6 SD (range). Differences between groups were analyzed using the
Student t test. Time-to-event data (nodules and cancer) was analyzed with the Kaplan-Meier
method. Survival curves have been evaluated with the log-rank test. Two different models
were considered. In the first, the thyroid score values determined the stratum levels, in the
second a list of covariates (TS, TSH, free T4, TPOAb, TGAb, T4 treatment) were used to test
the association with the failure time. The level of significance was set at 5%. Comparison
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between quantitative variables at diagnosis versus last visit was carried out using the
nonparametric Wilcoxon test.
2. Results
The main clinical characteristics, the thyroid function and morphology of the patients at
diagnosis and at last visit are reported in Table 1.
A. Thyroid Function and Morphology
At diagnosis, TSH ranged from 0 to 1000 mU/L and free T4 from 0.46 to 67.4 pg/mL. Five
patients had hyperthyroidism (0.55%), 697 were euthyroid (77.10%), 58 had subclinical
hypothyroidism (6.42%), and 144 had hypothyroidism (15.93%).
All patients with hypothyroidism commenced levothyroxine treatment immediately,
whereas those with subclinical hypothyroidismwere followed up and treatment started when
TSH concentrations exceeded 10mU/L according to the current recommendations [36]. At the
last visit 397 patients (43.92%) were on levothyroxine. In these patients, TSH and thyroid
volume decreased substantially during the follow-up, presumably as a result of treatment,
whereas the TS increased, indicating worsening of the echographic pattern.
At diagnosis, thyroid ultrasound revealed the presence of thyroid nodules in 77 children
(8.52%), with associated cervical adenopathy in 19 (24.6%); thyroid cancer was already
present in 3 of 77 (0.33%) children. At the last visit, the frequency of thyroid nodules had
increased substantially (174 children, 19.2%; P, 0.0001) compared with baseline, as well as
the frequency of cervical adenopathy (21 children, 12.1%; P , 0.05) and of thyroid cancer
within nodules (10 children, 5.7%; P , 0.0001).
The size of the nodules remained stable during follow-up, with slight volume changes in
both directions, independent from levothyroxine treatment. The incidence of thyroid nod-
ularity over 10-year follow-up is shown in Figure 1, with a calculated annual rate of 3.5%. The
probability of having a nodule is 9.3% at diagnosis, increasing to 43.9% after 10 years.
Cervical adenopathy by ultrasound at diagnosis of HT was observed at ultrasound in 183
subjects. Three children had already developed thyroid cancer at the time of the diagnosis of
HT, yielding a frequency of 1.64% of cancer among patients with cervical adenopathy.
FNA was performed in 97 suspicious nodules. Three tumors (2 papillary and 1 papillary
follicular variant) were identified at the time of diagnosis of HT by routine ultrasound. An
additionalr 7 cases (3 papillary follicular variant and 4 papillary) were identified during
follow-up. Specifically, 1 papillary and 2 papillary follicular variant were diagnosed after 1
year of follow- up, 1 papillary and 1 papillary follicular variant after 2 years, and 2 papillary
after 4 years (Fig. 1). Altogether, 10 cases of cancers (5 females and 5 males) were detected.
The clinical characteristics of these patients, ultrasound findings, morphological and cyto-
logical characteristics of the cancer, and TNM classification are reported in Table 2. All
patients had hard, firm, and enlarged cervical lymph nodes, frequently with ultra-
sound abnormalities, at the time of diagnosis. Uninodularity was present in 6 patients. At
Table 1. Clinical Characteristics, Thyroid Function and Morphology of the Patients at Diagnosis of
Hashimoto Thyroiditis and at the Last Visit
Chronological Age (y) Height (SD) BMI (SD) TSH mU/L
Diagnosis 10.6 6 3.2 20.07 6 1.17 0.07 6 1.17 20.0 6 80.4
(1–20.8) (24.9 – 3.2) (23.7– 3.9) (0–1000)
Last visit 15.1 6 3.1 20.11 6 1.19 0.19 6 3.49 4.5 6 18.3
(7.9–23.1) (23.9– 3.2) (23.8– 2.8) (0–422)
Pa ,0.0001
(Continued)
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ultrasound, the diameters ranged between 0.8 and 3 cm, with only one nodule ,1 cm di-
ameter. The nodules detected during follow-up showed progressive growth despite treatment
with levothyroxine. Six patients were euthyroid, 3 had subclinical hypothyroidism, and 1 was
hypothyroid. Among these patients, HT was diagnosed between 7.9 and 14 years of age.
According to cytology, four cases were TIR 5, three cases TIR 4 and two were TIR 3b [TIR (1
to 5) is the acronym used by the Italian thyroid cytology classification system]. According to
the TNM classification, three patients were pT1bN1aM0, two pT2N1aM0, one pT3N1bM0,
three pT3aN1aM0, and one pT3N1aM0. All patients had cervical metastases and none had
distal ones.All patientswith anormalFNAwere subsequently followedup; none developed cancer.
Table 1. Clinical Characteristics, Thyroid Function and Morphology of the Patients at Diagnosis of
Hashimoto Thyroiditis and at the Last Visit (Continued)
Free T4 pg/mL TPOAb U/mL TGAb U/mL Thyroid Volume (SD) TS
7.9 6 6.2 865 6 1671 672 6 1794 2.6 6 3.4 2.0 6 1.1
(0.46-–67.4) (0–14.250) (0–28160) (23.4–24.8) (0–4)
8.3 6 6.1 — — 1.8 6 3.2 2.6 6 1.1
(0.8–15.8) (24.3–23) (0–4)
NS ,0.0001 ,0.0001
Data are mean 6SD (range).
Normal values: TSH 0.3–3.69 mU/L; free T4 9–17.7 pg/mL; TPOAb , 35 U/mL; TGAb , 45 U/mL.
Abbreviation: NS, not significant.
aWilcoxon test.
Figure 1. Kaplan-Meier survival curve.
doi: 10.1210/js.2018-00287 | Journal of the Endocrine Society | 611
B. Kaplan-Meier Survival Analysis
Survival analysis (Table 3) showed that gender, celiac disease, T1DM, and family history for
autoimmune disease did not influence the rate of appearance of new thyroid nodules. The
incidence of new nodules was positively influenced by the TS (P , 0.001), TPOAb (P , 0.05),
and treatment with levothyroxine (P , 0.05). Furthermore, a positive correlation was found
between the development of cancer and TPOAb level (P , 0.01).
3. Discussion
The aim of this study was to investigate the influence of HT on the development of thyroid
nodules and/or thyroid cancer in a large cohort of children and adolescents. Our findings
clearly show that HT influences the development of thyroid nodular pathology but not of
cancer. These findings are comparable to those reported in adult subjects [37].
At the end of the follow-up period, the frequency of nodularity among the 904 patients with
HT was 19.2%, a figure substantially higher than that reported in children without HT (0.2%
to 5.1%) [15, 16]. This frequency is lower than that previously reported in another Italian
study (31.3%) [24], but similar to the studies of Skarpa et al. [38] and Keskin et al. [39] who
reported a prevalence of thyroid nodules in children and adolescent with HT of 14% and
13%, respectively.
In our study, the frequency of cancer within the thyroid nodules (5.7%) was similar to that
reported by Rago et al. (6.1%) [21] in a large cohort of adolescents and adult patients, and by
Keskin et al. (5.1%) [39] in a selected cohort of children and adolescents with HT. However, in
other studies the risk of thyroid cancer within thyroid nodules was higher, being 9.6% in the
cohort of Corrias et al. [24] and 9.4% in the study by Skarpa et al. [38].
In the current study, only 10 of 904 subjects (1.1%) developed thyroid cancer. The
prevalence of cancer in pediatric patients affected by HT has generally been reported to be
low, ranging from 0.67% in the study by Keskin et al. [39] to 3% in the study by Corrias et al.

































1 F N 14 14 14 Y N A
2 F N 12.2 16.8 16.8 Y N B
3 F Y 12.5 12.5 12.5 Y Y A
4 M N 12.8 12.8 13.9 Y N C
5 M N 12 13.9 16.1 Y N B
6 F Y 12,3 12,3 13,4 Y Y A
7 M N 7.9 7.9 7,9 Y Y A
8 F Y 10.6 10.6 12.6 Y N B
9 M N 11 11 11,6 Y N A
10 F Y 11.7 11.7 13.6 Y N A
(Continued)
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[24]. However, the reported prevalence is variable, and has been found to be as high as 58% of
subjects with HT in a large Chinese cohort [40] Ethnic and /or environmental differences
might account for these discrepancies. Other possibilities may also exist, such as the presence
in the Chinese children of an immunoglobulin G4-positiveHT, a condition strongly associated
with papillary thyroid carcinoma (PTC) [41, 42], or an overexpression of the oncogenic RET/
PTC rearrangement, a specific genetic alteration in patients with PTC that may also be
present in HT [43]. Last, methodological issues as well as patient selection may also account
for these differences.
The probability of having a thyroid nodule was 9.3% at diagnosis and increased to 43.9%
after 10 years of follow-up, resulting in a calculated annual incidence of 3.5%. We found no
influence of gender, celiac disease, T1DM, and family history of autoimmune disease on the
onset of new nodules, whereas a positive influence was observed for the TS, TPOAb, and
Table 3. Thyroid Nodule Development
Test of Equality Over Strata
Log Rank Ttest
Stratified Linear Rank Tests
Univariate x2 for the Wilcoxon Test
Gender P = 0.3365
Celiac disease P = 0.9941
T1DM P = 0.6152
Family history P = 0.1371
TS P , 0.001
TSH P = 0.8931
Free T4 P = 0.0431
TPOAb P = 0.0034
TGAb P = 0.6279
Comparison of survival curves and rank tests for the associations with covariates.
Table 2. Clinical Characteristics of the Patients with Cancer and Tumor Characteristics (Continued)









of the Nodules at
Diagnosis (cm)
Growth of the Nodule
A: None





U 1.1 A TIR 5 PTC pT1bN1a M0 Von
Willebrand
disease
U 1.3 D TIR 3b PTC pT1bN1a M0
M 2.1 A TIR 4 PTCfollicular
variant
pT3N1b M0
U 2.2 A TIR 4 PTCfollicular
variant
pT1bN1a M0
M 1.5 D TIR 4 PTC pT3aN1a M0 Addison
disease
M 3.0 A TIR 5 PTCfollicular
variant
pT3aN1a M0
U 1.5 A TIR 5 PTC pT3aN1a M0
U 1.0 C TIR 4 PTCfollicular
variant
pT2N1a M0
U 0,8 D TIR 5 PTC pT3N1aM0
M 2.4 B TIR 3b PTC pT2N1a M0
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treatment with levothyroxine. Because the TS, TPOAb, and treatment are related to the
morphological and functional impairment of the gland, we hypothesize that the inflammatory
state might favor the onset of nodules but not the development of cancer.
High TSH levels have been correlated with an increased frequency of papillary cancer in
adult patients with HT [44], but this correlation was not found in our cohort. This may be
because of the small number of patients with cancer in our study. Similar to previous findings
[20, 39, 45], all patients with cancer in our study had cervical lymphadenopathy. However,
cervical lymphadenopathy is frequent in children with or without HT and was also present
in a substantial number of noncancer patients with HT of our study. The presence of isolated
or multiple nodules or thyroid function at diagnosis are also not predictive of cancer risk. All
but one tumor had a diameter .1 cm, confirming that this threshold is a valid indication to
FNA. Our data also confirm that FNA should always be performed for nodules ,1 cm di-
ameter when there is a suspicious ultrasound appearance or in the presence of risk factors
such as extrathyroidal invasion, nodal metastasis, iodine deficiency, previous exposure to
radiation, in cancer survivors, and in patients with genetic syndromes orwith a family history
of thyroid cancer [18, 46].
The major limitations of this study are its retrospective nature, the comparison of results
obtained by different analytical methods, the multicenter selection of the patients and that
there was no central review of the thyroid ultrasound, FNA and/or surgical pathology.
On the other hand, this study’s major strength is the large number of children followed up
for a long period of time in the same centers of pediatric endocrinology using similar clinical
approaches, which allowed meaningful comparison of the data. The presence of skilled and
experienced pediatric ultrasonographers, and the adoption of a common echographic grading
score likely resulted in homogeneous ultrasound data.
Overall, the results of our study are reassuring because we found a low incidence of thyroid
cancer in our children and adolescents with HT, with no children having distant metastasis.
Moreover, considering the slow growth and the relatively favorable prognosis of these tumors
[47], we suggest that there is no need for frequent echographic evaluation (more than every
other year) in children with HT without any other risk factors. Similarly, measurement of
thyroid antibodies, which were used in this study asmarkers of thyroid inflammation, are not
useful in the management of patients after the initial diagnosis.
Even though the relation between HT and thyroid cancer remains an open issue, our data
suggest that in children and adolescents, HT is associated with an increased risk of de-
veloping thyroid nodules but not of thyroid cancer.
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